Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prescription medicines

- PMLiVE

FDA to assess safety of Boehringer’s Pradaxa

US regulator plans study to compare the anticoagulant with warfarin

- PMLiVE

GSK’s Anoro first LAMA/LABA approved for COPD in US

Important step towards eventually replacing Seretide/Advair sales

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

Good news for AZ on gout candidate lesinurad

Phase III trial backs planned filing in 2014

- PMLiVE

AZ donates Brixham lab to Plymouth University

Will create global research and education facility

- PMLiVE

AZ wins EU approval for four-strain flu vaccine

Fluenz Tetra offers competition to GSK’s Influsplit Tetra/Fluarix Tetra

- PMLiVE

AZ said to be eyeing Forest takeover bid

Financial Times says pharma companies are in early negotiations

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

- PMLiVE

Boehringer’s faldaprevir set for rapid review in Europe

More competition in emerging hepatitis C market

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links